Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Nkarta, Inc. (NKTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.36-0.66 (-5.07%)
At close: 04:00PM EDT
12.22 -0.14 (-1.13%)
After hours: 07:52PM EDT
Advertisement

Nkarta, Inc.

6000 Shoreline Court
Suite 102
South San Francisco, CA 94080
United States
415 582 4923
https://www.nkartatx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees135

Key Executives

NameTitlePayExercisedYear Born
Mr. Paul J. HastingsCEO, Pres & Director902.22kN/A1960
Dr. Nadir Mahmood Ph.D.Chief Financial & Bus. Officer591.24kN/A1979
Dr. Ralph Brandenberger Ph.D.Sr. VP of Technical OperationsN/AN/A1970
Dr. James Trager Ph.D., Ph.D.Chief Scientific OfficerN/AN/A1964
Mr. Greg MannVP of Public Affairs and Investor RelationsN/AN/AN/A
Dr. Alicia J. HagerChief Legal Officer & Corp. Sec.N/AN/A1970
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Corporate Governance

Nkarta, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 7. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement